Natalizumab-associated central nervous system lymphoma? - Another patient

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1653-1654

  Matzke, Mike ^a   Schreiber, Stefanie ^a   Elolf, Erck ^a   Metz, Imke ^b   Mawrin, Christian ^a   Heinze, Hans Jochen ^a   Sailer, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; CASE REPORT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMICALLY INDUCED; FATALITY; FEMALE; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIPLE SCLEROSIS; RISK FACTOR;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 84868029353     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512439336     Document Type: Letter

References (3)

1. Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009 ; 66: 403-406
2. DeAngelis LM. Primary central nervous system lymphomas. Curr Treat Options Oncol. 2001 ; 2: 309-318
3. Bourdette D, Neuwelt E, Doolittle N, Kraemer D. Reply. Ann Neurol. 2010 ; 67: 270-271